Advertorial: Croma-pharma: Made in Austria

Croma is investing heavily in in-house particular are outperforming research and development of new markets in aesthetic medicine. In products to drive the company’s May 2017, the Dermalfiller Princess Advertorial @aestheticsgroup @aestheticsjournaluk Aesthetics aestheticsjournal.com long-term growth through innovation. VOLUME was approved in China Croma In this context, Croma also promotes by the CFDA. Croma-Pharma was medical and pharmaceutical research in Austria. Today, more than 90% of the first European company to do so. Almost at the same time, the Croma-Pharma: Made in Austria sales are generated from products of our own research. company signed with Sihuan Pharma Becoming a global player with minimally invasive aesthetic medicine.

and, above all, gentler Croma-Pharma GmbH, is an international New headquarters and production treatments. Pain-free lunchtime procedures (treatments that are so pharmaceutical company based in Leobendorf, Austria. For over 40 years, Croma has been developing and producing innovative drugs and medical devices for plant as a clear commitment to expansion and location Due to the dynamic development of the company, the construction and expansion of Ltd. a long-standing license and the fields of ophthalmology, orthopedics the headquarters and another fully automatic straightforward that they can be distribution agreement. This joint and aesthetic dermatology. Croma is very production facility at the Leobendorf site was performed during a lunch break) venture with the third-largest proud to have made such an important initiated in 2015. The new headquarters was are designed to give the patient Chinese pharmaceutical company contribution to improving health and inaugurated in September 2017. a relaxed appearance. The expert is aimed at the approval of further quality of life for more than four decades. Founded in 1976 by pharmacist Gerhard Prinz, Croma is now managed by his sons Martin and Andreas Prinz. Since 2005, the Innovations as a result of intensive research and development Croma is investing heavily in in-house combination of different technologies optimises results and creates a longterm patient-doctor relationship. products and the nationwide distribution of these products in mainland China. company has been driven forward through Minimally invasive aesthetic medicine research and development of new products rapid internationalisation. In 2014, the to drive the company’s long-term growth has above-average growth potential Sustainability and social strategic sale of the Ophthalmology and through innovation. In this context, Croma in the global beauty market. In responsibility Orthopedics divisions took place, since then this area, Croma offers a steadily also promotes medical and pharmaceutical the company has specialised in minimally invasive aesthetic medicine. Currently, Croma has 12 international offices in Brazil, European Union and Switzerland and nearly research in Austria. Today, more than 90% of sales are generated from products of our own research. growing, well coordinated portfolio of products. The goal is a “full-face approach” to offer doctors and As a family business, Croma pursues a corporate policy based on ecological, economic and social 500 employees worldwide. patients the best solutions for all Aesthetic dermatology as a sustainability. For many years, Croma indications from a single source in dynamic future market is sponsor of the international Leading HA expert in Europe In modern aesthetic medicine, the trend familiar and reliable quality. organization “Light for the World”. Today Croma is a global player in the is moving from large, irreversible surgical With generous product donations dynamically growing segment of minimally invasive aesthetic medicine and is a leading European processor of hyaluronic acid. The company sells nearly six million hyaluronic lifts to smaller but more frequent, shorter and, above all, gentler treatments. Pain-free lunchtime procedures (treatments that are so straightforward that they can be performed Croma sets the course for entering the US market Croma makes an important contribution to the eye care in the poorest regions of the world. acid syringes (injectables) annually through In September 2018 Croma-Pharma during a lunch break) are designed to affiliates and a network of strategic GmbH (Croma) is establishing a joint give the patient a relaxed appearance. partnerships and distributors in more than 70 venture company with its long-time The expert combination of different countries. Production takes place exclusively partner Hugel, Inc. to develop and technologies optimises results and creates at the company headquarters in Leobendorf near Vienna, Austria. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, commercialise botulinum toxin, HA filler and PDO thread products in US, Canada, Australia and New Zealand. Contact a long-term patient-doctor relationship. Minimally invasive aesthetic medicine has above-average growth potential in the global beauty market. In this area, Croma a Platelet Rich Plasma (PRP) system and a offers a steadily growing, well coordinated Thus Croma unites its development CROMA-PHARMA GmbH personalised skincare technology in its core portfolio of products. The goal is a ‘full-face and marketing activities with a Stefanie Höhn strategic markets. strong partner in order to prepare approach’ to offer doctors and patients the Cromazeile 2 and implement the successful market A-2100 Leobendorf entry. The strategic partnership Aesthetics | February Phone: +43 676 846868 190 2020 with Hugel will continue Croma‘s Mail: stefanie.hoehn@croma.at international expansion efforts and Home: www.croma.at

best solutions for all indications from a single source in familiar and reliable quality.

Croma sets the course for entering the US market In September 2019 Croma-Pharma GmbH (Croma) establishded a joint venture company with its long-time partner Hugel, Inc. to develop and commercialise botulinum toxin, HA filler and PDO thread products in US, Canada, Australia and New Zealand. Thus Croma unites its development and marketing activities with a strong partner in order to prepare and implement the successful market entry. The strategic partnership with Hugel will continue Croma‘s international expansion efforts and further strengthen Croma‘s market position.

Milestones product approval and joint venture in China Asia in general and China in particular are outperforming markets in aesthetic medicine. In May 2017, the dermal filler Princess VOLUME was approved in China by the CFDA. Croma-Pharma was the first European company to do so. Almost at the same time, the company signed with Sihuan Pharma Ltd. a long-standing license and distribution agreement. This joint venture with the thirdlargest Chinese pharmaceutical company is aimed at the approval of further products and the nationwide distribution of these products in mainland China.

Sustainability and social responsibility As a family business, Croma pursues a corporate policy based on ecological, economic and social sustainability. For many years, Croma has been the sponsor of the international organisation “Light for the World”. With generous product donations Croma makes an important contribution to eye care in the poorest regions of the world.

Learn more about Croma’s products and services at croma.at Croma-Pharma GmbH Julian Popple: Country Manager UK Phone: +44 (0) 7442341 227 Email: julian.popple@cromapharma.com Orders: customerservice.uk@croma.at Website: www.croma.at

This article is written and supported by Croma-Pharma